Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 3 pages · Chinese
Release
Mabwell (Shanghai) Bioscience Co., Ltd. on 6ix
Earlier from Mabwell (Shanghai) Bioscience
- Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
- Announcement on Voluntary Disclosure of FDA Approval for the Clinical Trial Application for 6MW5311 Injection
- Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Engagement of H-share Audit Institution for 2026
Later from Mabwell (Shanghai) Bioscience
- Announcement on Voluntary Disclosure of Clinical Trial Applications for 9MW5211 Injection Approved by China NMPA
- Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
- Announcement on Voluntary Disclosure of the Approval by the National Medical Products Administration of the Clinical Trial Application for 9MW5211 Injection
- Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
- Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026
Follow Mabwell (Shanghai) Bioscience into a list and get an email when it puts out news.
Follow Mabwell (Shanghai) Bioscience